Close Menu

ado-trastuzumab-emtansine

The Phase III trial will compare Enhertu against Kadcyla as an adjuvant treatment for early-stage HER2-positive breast cancer patients.

However, the translational biomarker analysis suggested that high HER2 expression after neoadjuvant treatment may signal resistance to adjuvant Herceptin.